Carolina Do Rosário Esteves Guimarães

Carolina Do Rosário Esteves Guimarães

Auto-generated profile, based on publicly available information

Carolina Do Rosário Esteves Guimarães

Postgraduate Program in Pharmacy, Faculty of Pharmacy, Federal University of Bahia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2019 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
CGCarolina Do Rosário Esteves Guimarães
Carolina Do Rosário Esteves Guimarães
Humberto Fonseca de FreitasHumberto Fonseca de Freitas
Humberto Fonseca de Freitas
TBTânia Fraga Barros
Tânia Fraga Barros

5 February 2025 in Biofouling
Verified
Journal Article
Closed access
CGCarolina Do Rosário Esteves Guimarães
Carolina Do Rosário Esteves Guimarães
DGDanilo Santana Galvão
Danilo Santana Galvão
SCSilvio Cunha
Silvio Cunha
Humberto Fonseca de FreitasHumberto Fonseca de Freitas
Humberto Fonseca de Freitas
TBTânia Fraga Barros
Tânia Fraga Barros
Biofilms are a virulence factor for Candida albicans, a common pathogen in human fungal infections, making them resistant to many commercial antifungals. Therefore, the discovery of compounds that inhibit and eradicate biofilms is a priority. As thiosemicarbazones have had their effect on Candida biofilms little explored, this study investigated the inhibitory and eradication activity of 30 thiosemicarbazones and analogues against C. albicans biofilms. After initial screening, four compounds were selected and compound 28 emerged as the most potent with BIC50 at 31.55 ± 1.18 µM. By scanning electron microscopy analysis, blastoconidia adhered to the reduced surface and reduced formation of pseudohyphae and hyphae was revealed. Despite the inhibitory activity, the four compounds failed to eradicate the biofilm by more than 50%. Thus, the results suggest that the compounds evaluated are very promising for the development of effective antibiofilm compounds and open up new perspectives for elucidating the mechanism of action.

1 July 2022 in Research, Society and Development
Verified
Journal Article
Open access
PDF file
SCStefane dos Santos Carneiro
Stefane dos Santos Carneiro
Humberto Fonseca de FreitasHumberto Fonseca de Freitas
Humberto Fonseca de Freitas
CGCarolina Do Rosário Esteves Guimarães
Carolina Do Rosário Esteves Guimarães
Commercially, there are many products sold as probiotics composed by Sacharomyces boulardii, with probiotic drugs being those that are widely used in different clinical situations. The probiotic efficacy of these agents is proven in many studies, as well as their safety in normal use situations. However, there have been some reports of fungemias related to the use of these probiotics in hospitals associated with some factors. Therefore, our objective is to review the knowledge about this association, focusing on the factors that provide it and the development mechanisms. For the development of fungemia associated with the use of probiotics, it is observed that it has greater development potential in patients using a central venous catheter. Although this is the main factor, others that reduce the patient's immune status, as well as reduce the intestinal defense barriers, contribute to this process, increasing the risk of fungemia. Despite the well-documented benefits of probiotics, their use must be carefully evaluated for each patient, due to factors that contribute to associate the use of probiotic drugs with the risk of developing bloodstream infection by S. boulardii. It is necessary, therefore, to include protocols that generate alerts about this risk and establish preventive measures.